Princeton-based Made Scientific and Hemogenyx Pharmaceuticals plc announced Sept. 8 a manufacturing partnership to advance HG-CT-1, Hemogenyx’s chimeric antigen receptor T-cell (CAR-T) therapy and lead clinical program for the treatment of relapsed/refractory acute myeloid leukemia (r/r AML) in adults.
Under the agreement, Hemogenyx will leverage Made Scientific’s specialized expertise in CAR-T cell therapy technology transfer and manufacturing at its GMP facilities in Newark and Princeton, which are equipped for both clinical and commercial manufacturing.
The collaboration will advance Hemogenyx’s ongoing Phase I clinical trial of HG-CT-1 in adult patient cohorts and support the potential inclusion of additional cohorts for pediatric r/r AML patients. Hemogenyx has already made significant progress in the trial, with early clinical data supporting growing confidence in both safety and potential efficacy.
“Our collaboration with Hemogenyx reflects Made Scientific’s commitment to advancing next-generation cell therapies that address urgent, unmet medical needs,” said Syed T. Husain, chairman and CEO of Made Scientific. “Through our integrated development and manufacturing solutions and highly experienced team, we are proud to support Hemogenyx as they advance HG-CT-1 in their Phase I clinical trial.”
